{"schema_version":"secwatch.filing_event.v1","accession":"0000879169-24-000169","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2024-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.205080+00:00","generated_at":"2026-05-30T09:31:25.946656+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Incyte Q3 2024 revenues up 24% to $1.14B; Jakafi guidance raised","bullets":["Total revenues $1.138B (+24% YoY); Jakafi net revenue $741M (+16%); Opzelura $139M (+52%).","GAAP diluted EPS $0.54 vs $0.76 YoY; Non-GAAP diluted EPS $1.07 vs $1.10.","Jakafi 2024 guidance raised to $2.74-2.77B; Other Heme/Onco guidance reduced to $310-320M.","FDA approved Niktimvo (axatilimab) for chronic GVHD; sNDA filed for ruxolitinib cream in pediatric AD.","Phase 3 retifanlimab in SCAC and tafasitamab in FL met endpoints; sBLAs planned by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000879169-24-000169","json":"https://secwatch.observer/filing/0000879169-24-000169.json","markdown":"https://secwatch.observer/filing/0000879169-24-000169.md","text":"https://secwatch.observer/filing/0000879169-24-000169.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000087916924000169/0000879169-24-000169-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000087916924000169/incy-20241029.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T09:31:25.946656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}